Blog
RSS FeedPosted by Michael Wonder on 27 Feb 2024
Tafamidis for the treatment of patients with transthyretin amyloidosis with cardiomyopathy
27 February 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 26 Feb 2024
Setmelanotide acetate for the treatment of people with obesity and hyperphagia associated with Bardet-Biedl syndrome (draft guidance)
22 February 2024 - NICE has published further draft guidance on the use of setmelanotide acetate. ...
Posted by Michael Wonder on 22 Feb 2024
Up to 14,000 people could benefit from the first treatment for severe alopecia recommended by NICE
22 February 2024 - Thousands of people with severe hair loss due to alopecia areata are set to benefit from a ...
Posted by Michael Wonder on 21 Feb 2024
Talazoparib tosylate for the treatment of patients with advanced BRCA mutation positive HER2 negative breast cancer (final guidance)
21 February 2024 - NICE has published final evidence-based recommendations on the use of talazoparib tosylate (Talzenna) for the treatment ...
Posted by Michael Wonder on 10 Feb 2024
Isatuximab in combination with pomalidomide and dexamethasone for the treatment of patients with relapsed and refractory multiple myeloma
9 February 2024 - NICE is reviewing its guidance on the use of isatuximab for the treatment of patients with ...
Posted by Michael Wonder on 07 Feb 2024
Olaparib in combination with abiraterone acetate for the treatment of patients with hormone relapsed metastatic prostate cancer
7 February 2024 - NICE has published final evidence-based recommendations on the use of olaparib (Lynparza) in combination with abiraterone ...
Posted by Michael Wonder on 07 Feb 2024
Nivolumab with relatlimab for the treatment of patients with unresectable or metastatic melanoma
7 February 2024 - NICE has published final evidence-based recommendations on the use of nivolumab with relatlimab (Opdualag) for the ...
Posted by Michael Wonder on 07 Feb 2024
Belumosudil mesylate for the treatment of patients with chronic graft versus host disease
7 February 2024 - NICE has published final evidence-based recommendations on the use of belumosudil mesylate (Rezurock) for the treatment ...
Posted by Michael Wonder on 06 Feb 2024
Updates on NICE and SMC collaboration on MTA for cystic fibrosis
1 February 2024 - On 19 December 2023, we advised that NICE would be liaising with key stakeholders to determine ...
Posted by Michael Wonder on 05 Feb 2024
Linzagolix choline for the treatment of patients with moderate to severe symptoms of uterine fibroids
5 February 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...
Posted by Michael Wonder on 05 Feb 2024
Call for time limits on PHARMAC's drug assessment process
4 February 2024 - The Cancer Society says it is great to see the new government invest in cancer drugs, ...
Posted by Michael Wonder on 05 Feb 2024
Selinexor in combination with bortezomib and dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma
2 February 2024 - The Department of Health and Social Care has asked the NICE to produce guidance on the ...
Posted by Michael Wonder on 04 Feb 2024
Ruxolitinib phosphate for the treatment of patients with non-segmental vitiligo
31 January 2024 - The Department of Health and Social Care has asked NICE to produce guidance on using ruxolitinib ...
Posted by Michael Wonder on 02 Feb 2024
Fenfluramine hydrochloride for the treatment of patients with Lennox-Gastaut seizures
31 January 2024 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 01 Feb 2024
Ivosidenib for the treatment of patients with advanced IDH1 R132 mutation positive cholangiocarcinoma after one or more systemic treatments
31 January 2024 - NICE has published final evidence-based recommendations on the use of ivosidenib (Tibsovo) for the treatment of ...